IMGN779 is a novel ADC that is a potential treatment for cancers that express CD33, including acute myeloid leukemia (AML).

IMGN779 combines a high-affinity, humanized anti-CD33 antibody, a cleavable disulfide linker, and one of ImmunoGen’s novel indolino-benzodiazepine payloads, called IGNs, which alkylate DNA without crosslinking. It is in Phase I clinical testing.

Learn more about our IMGN779 Clinical Trials
Learn more about IMGN779 Publications